Table 1– Proteasome function in chronic lung disease
Lung cancerTherapeutic application of proteasome inhibitors inhibits lung tumour growth, induces apoptosis, reduces metastatic potential and overcomes drug resistance[48, 49]
AsthmaProteasome inhibitors reduce allergen-induced pulmonary eosinophilia in sensitised rats[50]
Rationale for proteasome inhibition as a therapeutic approach to counteract NF-κB signalling in asthma[51]
Bortezomib treatment fails to ameliorate chronic asthma in mice[52]
Pulmonary fibrosisProteasome inhibition does not reduce bleomycin-induced pulmonary fibrosis in mice[53]
The proteasome inhibitor bortezomib attenuates bleomycin-induced pulmonary fibrosis[47]
Cystic fibrosisProteasomal degradation of mutant CFTR and ENaC via the ERAD pathway[54–56]
Proteasome inhibition rescues CFTR degradation and partially restores cell function[57, 58]
COPDDiaphragm atrophy is associated with increased proteasome activity in COPD patients[59]
Proteasome inhibition counteracts diaphragm atrophy in mice[60]
Downregulation of proteasome expression and activity in lungs of COPD patients[61]
  • COPD: chronic obstructive pulmonary disease; NF-κB: nuclear factor κB; CFTR: cystic fibrosis transmembrane conductance regulator; ENaC: epithelial Na+ channel; ERAD: endoplasmic reticulum-associated degradation.